MSS 22103

BUSINESS RESEARCH METHODOLOGY

BACHELOR OF ISLAMIC WEALTH MANAGEMENT
SEMESTER 5B
PROF DR. ZAINUDIN BIN AWANG
INVESTMENT PORTFOLIO OF RM 100 000

GROUP 4: PHARMA & HARTALEGA

NO. NAME MATRIC NO.

1. SITI NORHANNA BINTI MOHD AZAN 051264
2. HALIMATUSSAADIAH BINTI KHAIRUDDIN 051291
3. KHAIRUL BARIAH BINTI ISMAIL 051178
4. NURUL HANUM IZZAH BINTI ZAHRAN 051249
5. AINA SYAZWANI BINTI HARUN 049938

TABLE OF CONTENT
1.0 PHARMANIAGA BERHAD ……………………………………………………..

1.1 COMPANY BACKGROUND……………………………………………. 1

1.2 REASON………………………………………………………………….. 1

1.3 FINANCIAL SUMMARY………………………………………….…….. 2

1.4 FINANCIAL ANALYSIS………………………………………………… 3

2.0 HARTALEGA HOLDING BERHAD…………………………………………..

2.1 COMPANY BACKGROUND……………………………………………. 4

2.2 REASON………………………………………………………………….. 4

2.3 FINANCIAL SUMMARY……………………………………………… 5

2.4 FINANCIAL ANALYSIS………………………………………………… 7

1.0 PHARMANIAGA BERHAD

Date Stock Quantity Price Current Price Capital used

code/name of lot purchased (RM) (RM)
(RM)
7 December 2020 7081 93 5.35 5.35 49755

1.1 COMPANY BACKGROUND

Pharmaniaga Berhad is a Malaysian integrated pharmaceutical group. The ambit of their

business interests ranges from warehousing and distribution of pharmaceutical and medical
products, manufacturing of generic pharmaceuticals, marketing and sales; research and
development; trading and installation of medical and hospital equipment as well as
community pharmacy. Pharmaniaga was established in 1994 as Remedi Pharmaceuticals. The
company was renamed as Pharmaniaga in August 1998 and is the first healthcare company in
Malaysia to be listed in the Main Market of Kuala Lumpur Stock Exchange (now Bursa
Malaysia). As an entity listed on the Main Board of Bursa Malaysia Securities Berhad with a
strong domestic presence, the company is steadily growing their business presence through
their expansion initiatives.

1.2 REASON

Pharmaniaga Bhd is planning to produce its own halal-certified vaccines within the next
five years. The pharmaceutical group is currently completing the upgrading works at its
manufacturing site Puchong, Selangor, which has received the halal status from the
Department of Islamic Development Malaysia (Jakim). The facility is expected to be in full
operation for vaccine production in 2024.

Their board has approved to go ahead with the halal vaccine production project, which
includes the upgrading of their facilities as well as the production of their own halal vaccines
produced by Pharmaniaga, which is planned to be executed in four to five years. The vaccine
will be the first halal-certified vaccine for the company and will be marketed globally, as
supposed to the vaccines that they are currently doing the fill-and-finish, currently only being
marketed in Malaysia.

1
1.3 FINANCIAL SUMMARY

2
1.4 FINANCIAL ANALYSIS
Pharmaniaga Berhad is a company about heath care. Through the annual report, we can see that every
year the company gain benefit as their revenue increase each year. In 2015 and 2016, the company get
RM 2.2 billion of their revenue while in 2017, they gain RM 2.3 billion and RM 2.4 billion in 2018.
For the year of 2019, they get higher of the revenue compared to previous years which is RM 2.8
billion.

While for profit, the company get an unstable value where in 2015, they get RM 84 million while in
2016, they are having a loss where they only get RM 45.6 million. However, in 2017, they are having
an increasing which they get RM 53.8 million. Still, in 2018, they are having a loss again where they
get RM 42.5 million in that year. Luckily, in the year 2019, the company having a blessing where they
get RM 149.2 million of the profit.

The earnings per share gain by the company each year having a same as profit where they are having
a loss and profit different year. In 2015, they gain RM 32.5 cent of the share while in 2016, they
involve with losing where they only gain RM 17.6 cent. But, in 2017, the company gain higher than
previous year which is RM 20.7 cent of the share. In 2018, again they are getting into loss where they

3
gain only RM 16.3 cent. However, in 2019, the company get RM 57.2 cent where it is the highest in
the period.

2.0 HARTALEGA HOLDINGS BERHAD

Date Stock Quantity Price Current Price Capital used

code/name of lot purchased (RM) (RM)
(RM)
2 December 2020 5168 35 14.28 14.440 49980

2.1 COMPANY BACKGROUND

Hartalega Holding Bhd was established in 1988, Hartalega is the world’s largest nitrile glove
producer, manufacturing 14 billion gloves annually. It exports to the Americas, Europe, Asia Pacific
and Middle East. Hartalega was founded in 2006 and based in Kuala Lumpur, Malaysia. The
company is listed on Bursa Malaysia under the Main Market. Launched the world’s first 4.7g nitrile
glove. It mimicked the stretchiness and softness of natural rubber gloves without protein allergy risks,
was competitively priced and outside the Tillotson’s patent was the first company to introduce soft
stretchy nitrile gloves, emulating the natural properties of natural rubber latex.

2.2 REASON

The Covid-19 outbreak in late January 2020 has seen an overwhelming demand for gloves.
Beginning in China, this evolved into a deadly pandemic subsequently affecting the US, the EU and
countries around the world. Reports have indicated that amid this pandemic, the usage of gloves in
hospitals has increased substantially. Hartalega is one of the companies that receives high demand for
their products. In August, Hartalega Holding Berhad's share price rose past RM20 for the first time, as
doubt about the development of a Covid-19 vaccine led to buying healthcare-related shares on Bursa
Malaysia.

4
2.3 FINANCIAL SUMMARY

5
6
2.4 FINANCIAL ANALYSIS